


Prosultiamine

Chemical Properties

CAS No. :	59-58-5
Formula:	C ₁₅ H ₂₄ N ₄ O ₂ S ₂
Molecular Weight:	356.51
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Prosultiamine is commonly used for treatment of beriberi, nutritional disorders caused by lack of vitamin B1, etc.
Targets(IC50)	Apoptosis,Others,Caspase

Solubility Information

Solubility	DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.805 mL	14.0249 mL	28.0497 mL
5 mM	0.561 mL	2.805 mL	5.6099 mL
10 mM	0.2805 mL	1.4025 mL	2.805 mL
50 mM	0.0561 mL	0.2805 mL	0.561 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. *Int J Urol.* 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1. PubMed PMID: 28965354.

Ogawa T, Kato T, Ono M, Shimizu T. [Clinical and MRI Findings in Patients with Congenital Anosmia]. *Nihon Jibiinkoka Gakkai Kaiho.* 2015 Aug;118(8):1016-26. Japanese. PubMed PMID: 26548095.

Kira J. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). *BMC Med.* 2013 Aug 15;11:183. doi: 10.1186/1741-7015-11-183. PubMed PMID: 23945332; PubMed Central PMCID: PMC3826871.

Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, Matsuzaki T, Nishiura Y, Nagasato K, Narita-Masuda T, Nakamura H, Satoh K, Sasaki H, Sakai H, Kawakami A. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. *BMC Med.* 2013 Aug 15;11:182. doi: 10.1186/1741-7015-11-182. PubMed PMID: 23945290; PubMed Central PMCID: PMC3826868.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481